Pasar al contenido principal

MECANISMOS DE MITOSIS Y RECAMBIO CELULAR EN TIROIDES NORMAL, HIPERPLASIA, Y CANCER

PID2022-140149OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions

  • Chong, Anne Sophie
  • Roca, Carla
  • Morales Sánchez, Paula
  • Dorca, Eduard
  • Barea, Verónica
  • Ruz Caracuel, Ignacio
  • Valderrabano, Pablo
  • Rovira, Carlota
  • Jou, Cristina
  • Bouron Dal Soglio, Dorothée
  • Chernock, Rebecca
  • Torrezan, Giovana
  • Pusztaszeri, Marc
  • Cameselle Teijeiro, José
  • Matias-Guiu, Xavier
  • Alvarez, Clara
  • Salvador, Héctor
  • Wasserman, Jonathan
  • Leandro García, Luis Javier
  • Foulkes, William
  • Andrés León, Eduardo
  • Casano Sancho, Paula
  • Rivera, Barbara
Germline and somatic changes in DICER1 and DGCR8 microprocessors confer risk of developing benign and malignant thyroid lesions, yet the molecular events driving malignant transformation remain unclear. We trace the molecular trajectories from benignity to malignancy in DICER1- and DGCR8-mutated thyroid lesions using multiomic profiling on over 30 DICER1-/DGCR8-mutated samples. Our findings reveal a progressive, specific, and linear accumulation of genetic changes, which when combined with enhanced downregulation of miRNAs distinguished DICER1-/DGCR8-malignant lesions from their benign counterparts. Compensatory hypomethylation of miRNA-encoding genes characterized DICER1-/DGCR8-benign lesions, but as the tumors progressed to malignancy, methylation was partly reimposed, reversing the attempts to activate miRNA-encoded genes and further compromising miRNA production. Transcriptomic analyses revealed mutation-specific effects on the microenvironment, whereby DICER1 mutations activated canonical thyroid cancer progression pathways, whereas altered DGCR8 associated with immune-related changes. This work unveils specific molecular events underlying malignant progression of miRNA-biogenesis-related thyroid tumors and identifies potential biomarkers and disease etiology mechanisms., Fundación Científica Asociación Española Contra el Cáncer (AECC) (grant LABAE235269RIVE) to BR. • Fundación Mutua Madrileña (grant AP173972020) to BR. • Fundación La Marató de TV3 (grant 202031-10) to BR. • Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (grant 2021 SGR 01066) to BR. • Instituto de Salud Carlos III (ISCIII) and the European Social Fund: Investing in Your Future (grant CP21/00038) to BR. • “La Caixa” Foundation (ID 100010434) fellowship LCF/BQ/DI21/11860051 to ASC. • Agencia Estatal de Investigación (grant PID2022-140149OB-I00) to CVA and to the TIROCHUS collection [Rnb code: ISCIII-BIO-2012/000026]). • ISCIII (grant PI23/00722) to JMCT. • Fundação de Amparo à Pesquisa do Estado de São Paulo (grants 2018/06269-5 and 2020/00870-9) to GTT. • Comunidad de Madrid (funding for the iTIRONET Consortium [P2022/BMD7379], of which LJLG, PV, and IRC are members).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

  • Rodrigues, Joana S.
  • Chenlo, Miguel
  • Bravo, Susana B.
  • Pérez-Romero, Sihara
  • Suarez-Fariña, Maria
  • Sobrino, Tomás
  • Sanz-Pamplona, Rebeca
  • González-Prieto, Román
  • Blanco Freire, Manuel Narciso
  • Nogueiras, Ruben
  • López, Miguel
  • Fugazzola, Laura
  • Cameselle-Teijeiro, José Manuel
  • Álvarez, Clara V.
The E3 SUMO ligase PIAS2 is expressed at high levels in differentiated papillary thyroid carcinomas but at low levels in anaplastic thyroid carcinomas (ATC), an undifferentiated cancer with high mortality. We show here that depletion of the PIAS2 beta isoform with a transcribed double-stranded RNA-directed RNA interference (PIAS2b-dsRNAi) specifically inhibits growth of ATC cell lines and patient primary cultures in vitro and of orthotopic patient-derived xenografts (oPDX) in vivo. Critically, PIAS2b-dsRNAi does not affect growth of normal or non-anaplastic thyroid tumor cultures (differentiated carcinoma, benign lesions) or cell lines. PIAS2b-dsRNAi also has an anti-cancer effect on other anaplastic human cancers (pancreas, lung, and gastric). Mechanistically, PIAS2b is required for proper mitotic spindle and centrosome assembly, and it is a dosage-sensitive protein in ATC. PIAS2b depletion promotes mitotic catastrophe at prophase. High-throughput proteomics reveals the proteasome (PSMC5) and spindle cytoskeleton (TUBB3) to be direct targets of PIAS2b SUMOylation at mitotic initiation. These results identify PIAS2b-dsRNAi as a promising therapy for ATC and other aggressive anaplastic carcinomas., This work was supported by Agencia Estatal de Investigación (AEI, Spain), co-funded by the European Union, projects’ codes BFU2013-46109-R, BFU2016-76973-R, PID2019-110437RB-I00, PDC2021-121621-I00 and PID2022-140149OB-I00 to C.V.A. This work has received financial support from the Xunta de Galicia (Centro singular de investigación de Galicia accreditation 2019-2022) and the European Union (European Regional Development Fund - ERDF). J.M.C.-T. is supported by grant no. ISCIII-PI23/00722, and PI19/01316 from Instituto de Salud Carlos III, State Research Agency (Spain), co-funded by the European Union. L.F. is funded by Italian Ministry of Health - Ricerca Corrente. T.S. is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III, Ref. CPII17/00027, co-funded by the European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions

  • Chong, Anne-Sophie
  • Roca, Carla
  • Morales-Sánchez, Paula
  • Dorca, Eduard
  • Barea, Verónica
  • Ruz, Ignacio
  • Valderrábano, Pablo
  • Rovira, Carlota
  • Jou, Cristina
  • Bouron, Dorothée
  • Chernock, Rebecca D.
  • Torrezan, Giovana T.
  • Pusztaszeri, Marc
  • Cameselle, José M.
  • Matías-Guiu, Xavier
  • Álvarez, Clara V.
  • Salvador, Héctor
  • Wasserman, Jonathan D.
  • Leandro-García, Luis Javier
  • Foulkes, William D.
  • Andrés-León, Eduardo
  • Casano-Sancho, Paula
  • Rivera, Bárbara
Germline and somatic changes in DICER1 and DGCR8 microprocessors confer risk of developing benign and malignant thyroid lesions, yet the molecular events driving malignant transformation remain unclear. We trace the molecular trajectories from benignity to malignancy in DICER1- and DGCR8-mutated thyroid lesions using multiomic profiling on over 30 DICER1-/DGCR8-mutated samples. Our findings reveal a progressive, specific, and linear accumulation of genetic changes, which when combined with enhanced downregulation of miRNAs distinguished DICER1-/DGCR8-malignant lesions from their benign counterparts. Compensatory hypomethylation of miRNA-encoding genes characterized DICER1-/DGCR8-benign lesions, but as the tumors progressed to malignancy, methylation was partly reimposed, reversing the attempts to activate miRNA-encoded genes and further compromising miRNA production. Transcriptomic analyses revealed mutation-specific effects on the microenvironment, whereby DICER1 mutations activated canonical thyroid cancer progression pathways, whereas altered DGCR8 associated with immune-related changes. This work unveils specific molecular events underlying malignant progression of miRNA-biogenesis-related thyroid tumors and identifies potential biomarkers and disease etiology mechanisms., Fundación Científica Asociación Española Contra el Cáncer (AECC) (grant LABAE235269RIVE) to BR. -- Fundación Mutua Madrileña (grant AP173972020) to BR. -- Fundación La Marató de TV3 (grant 202031-10) to BR. -- Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (grant 2021 SGR 01066) to BR. -- Instituto de Salud Carlos III (ISCIII) and the European Social Fund: Investing in Your Future (grant CP21/00038) to BR. “La Caixa” Foundation (ID 100010434) fellowship LCF/BQ/DI21/11860051 to ASC. -- Agencia Estatal de Investigación (grant PID2022-140149OB-I00) to CVA and to the TIROCHUS collection [Rnb code: ISCIII-BIO-2012/000026]). -- ISCIII (grant PI23/00722) to JMCT. -- Fundação de Amparo à Pesquisa do Estado de São Paulo (grants 2018/06269-5 and 2020/00870-9) to GTT. -- Comunidad de Madrid (funding for the iTIRONET Consortium [P2022/BMD7379], of which LJLG, PV, and IRC are members)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tracing the molecular route to progression in miRNA-biogenesis-defective thyroid lesions

  • Chong, Anne Sophie
  • Roca, Carla
  • Morales Sánchez, Paula
  • Dorca, Eduard
  • Barea, Verónica
  • Ruz Caracuel, Ignacio
  • Valderrabano, Pablo
  • Rovira, Carlota
  • Jou, Cristina
  • Bouron Dal Soglio, Dorothée
  • Chernock, Rebecca
  • Torrezan, Giovana
  • Pusztaszeri, Marc
  • Cameselle Teijeiro, José
  • Matias-Guiu, Xavier
  • Alvarez, Clara
  • Salvador, Héctor
  • Wasserman, Jonathan
  • Leandro García, Luis Javier
  • Foulkes, William
  • Andrés León, Eduardo
  • Casano Sancho, Paula
  • Rivera, Barbara
Germline and somatic changes in DICER1 and DGCR8 microprocessors confer risk of developing benign and malignant thyroid lesions, yet the molecular events driving malignant transformation remain unclear. We trace the molecular trajectories from benignity to malignancy in DICER1- and DGCR8-mutated thyroid lesions using multiomic profiling on over 30 DICER1-/DGCR8-mutated samples. Our findings reveal a progressive, specific, and linear accumulation of genetic changes, which when combined with enhanced downregulation of miRNAs distinguished DICER1-/DGCR8-malignant lesions from their benign counterparts. Compensatory hypomethylation of miRNA-encoding genes characterized DICER1-/DGCR8-benign lesions, but as the tumors progressed to malignancy, methylation was partly reimposed, reversing the attempts to activate miRNA-encoded genes and further compromising miRNA production. Transcriptomic analyses revealed mutation-specific effects on the microenvironment, whereby DICER1 mutations activated canonical thyroid cancer progression pathways, whereas altered DGCR8 associated with immune-related changes. This work unveils specific molecular events underlying malignant progression of miRNA-biogenesis-related thyroid tumors and identifies potential biomarkers and disease etiology mechanisms., Fundación Científica Asociación Española Contra el Cáncer (AECC) (grant LABAE235269RIVE) to BR. • Fundación Mutua Madrileña (grant AP173972020) to BR. • Fundación La Marató de TV3 (grant 202031-10) to BR. • Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (grant 2021 SGR 01066) to BR. • Instituto de Salud Carlos III (ISCIII) and the European Social Fund: Investing in Your Future (grant CP21/00038) to BR. • “La Caixa” Foundation (ID 100010434) fellowship LCF/BQ/DI21/11860051 to ASC. • Agencia Estatal de Investigación (grant PID2022-140149OB-I00) to CVA and to the TIROCHUS collection [Rnb code: ISCIII-BIO-2012/000026]). • ISCIII (grant PI23/00722) to JMCT. • Fundação de Amparo à Pesquisa do Estado de São Paulo (grants 2018/06269-5 and 2020/00870-9) to GTT. • Comunidad de Madrid (funding for the iTIRONET Consortium [P2022/BMD7379], of which LJLG, PV, and IRC are members).